Keyphrases
Adverse Events of Special Interest
16%
Candida Infection
16%
Chronic mucocutaneous Candidiasis
16%
Clinical Trials
100%
Confidence Interval
16%
Exposure-adjusted Incidence Rate
16%
High Affinity
16%
Incidence Rate
50%
Induction Period
16%
Infection Rate
16%
Integrated Safety
16%
Interleukin-17 (IL-17)
16%
Ixekizumab
100%
Long-term Maintenance
16%
Long-term Safety
100%
Long-term Treatment
16%
Maintenance Interval
16%
Maintenance Treatment
16%
Moderate-to-severe Psoriasis
100%
Monoclonal Antibody
16%
Opportunistic Infections
16%
Oral Candida
16%
Psoriasis
33%
Safety Data
33%
Safety Profile
100%
Safety Signal
16%
Serious Adverse Events
16%
Treatment-related Adverse Events
16%
Medicine and Dentistry
Adverse Event
50%
Candidiasis
16%
Clinical Study
16%
Clinical Trial
100%
Disease
16%
Interleukin 17
16%
Ixekizumab
100%
Maintenance Therapy
16%
Monoclonal Antibody
16%
Mucocutaneous Candidiasis
16%
Opportunistic Infection
16%
Psoriasis
33%
Psoriasis Vulgaris
100%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
50%
Candidiasis
16%
Clinical Study
16%
Clinical Trial
100%
Disease
16%
Interleukin 17
16%
Ixekizumab
100%
Monoclonal Antibody
16%
Mucocutaneous Candidiasis
16%
Opportunistic Infection
16%
Psoriasis
33%
Psoriasis Vulgaris
100%